

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Selexipag

June 1, 2020

Therapeutic category

Cardiovascular agents-miscellaneous

Non-proprietary name

Selexipag

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0608-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 8, 2017 (New instructions): Revised language is underlined.

Current		Revision													
<p>2. CONTRAINDICATIONS</p> <p><u>Patients receiving preparations containing clopidogrel</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration</p> <table border="1"> <thead> <tr> <th><u>Drugs</u></th> <th><u>Signs, symptoms, and treatment</u></th> <th><u>Mechanism/risk factors</u></th> </tr> </thead> <tbody> <tr> <td><u>Preparations containing clopidogrel</u></td> <td><u>The blood concentration of the active metabolite of this drug may increase.</u></td> <td><u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u></td> </tr> </tbody> </table> <p>10.2 Precautions for Co-administration (N/A)</p>		<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>	<u>Preparations containing clopidogrel</u>	<u>The blood concentration of the active metabolite of this drug may increase.</u>	<u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u>	<p>2. CONTRAINDICATIONS (deleted)</p> <p>10. INTERACTIONS (deleted)</p> <p>10.2 Precautions for Co-administration</p> <table border="1"> <thead> <tr> <th><u>Drugs</u></th> <th><u>Signs, symptoms, and treatment</u></th> <th><u>Mechanism/risk factors</u></th> </tr> </thead> <tbody> <tr> <td><u>Agents with CYP2C8 inhibiting effects (preparations containing Clopidogrel, deferasirox, etc.)</u></td> <td><u>There are reports that the C_{max} and AUC of the active metabolite of selexipag increased following co-administration with clopidogrel. If these drugs are initiated during the treatment with selexipag, a dose reduction of selexipag should be considered. If selexipag is initiated</u></td> <td><u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u></td> </tr> </tbody> </table>		<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>	<u>Agents with CYP2C8 inhibiting effects (preparations containing Clopidogrel, deferasirox, etc.)</u>	<u>There are reports that the C_{max} and AUC of the active metabolite of selexipag increased following co-administration with clopidogrel. If these drugs are initiated during the treatment with selexipag, a dose reduction of selexipag should be considered. If selexipag is initiated</u>	<u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u>
<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>													
<u>Preparations containing clopidogrel</u>	<u>The blood concentration of the active metabolite of this drug may increase.</u>	<u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u>													
<u>Drugs</u>	<u>Signs, symptoms, and treatment</u>	<u>Mechanism/risk factors</u>													
<u>Agents with CYP2C8 inhibiting effects (preparations containing Clopidogrel, deferasirox, etc.)</u>	<u>There are reports that the C_{max} and AUC of the active metabolite of selexipag increased following co-administration with clopidogrel. If these drugs are initiated during the treatment with selexipag, a dose reduction of selexipag should be considered. If selexipag is initiated</u>	<u>Metabolism of the active metabolite of this drug is considered to be suppressed due to inhibition of CYP2C8.</u>													

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

		<u>during the treatment with these drugs, the initial dosing frequency of selexipag should be reduced to once daily.</u>	
--	--	--	--

N/A: Not Applicable, because the section is not included in the current package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp